• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • SPORE In Prostate Cancer
    • External Funding Opportunities
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Health Plans and Financial Matters
    • Maps and Directions
    • myUCLAhealth
    • Patient Testimonials
    • Preparing for Surgery
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • SPORE Lectures
    • External Funding Opportunities
  • Expert Team
    • Board of Directors
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Clinical Trials

Clinical Trials

Clinical Trials

  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  • What Is a Clinical Trial?
  • Who Should Consider Clinical Trials & Why
  • Bladder Cancer Clinical Trials
  • Kidney Cancer Clinical Trials
  • Prostate Cancer Clinical Trials
  • Clinical Research Team
  • IUO Membership Study Information
  1. Home
  2. Institute of Urologic Oncology
  3. Clinical Trials
  4. Hypo-fractionated Stereotactic Body Radiotherapy in High Risk Prostate Cancer

Hypo-fractionated Stereotactic Body Radiotherapy in High Risk Prostate Cancer

Share this

Hypo-fractionated Stereotactic Body Radiotherapy in High Risk Prostate Cancer

Observational Trial:  HR SBRT Prostate

A Study That Obtains Quality of Life Data after a Short Course of Radiation Therapy

Technical Title:  A Study to Obtain Quality of Life Data after a Hypo-Fractionated Course of Stereotactic Body Radiotherapy for the Treatment of Localized High-Risk Prostate Cancer

UCLA Department of Radiation Oncology is conducting a study that researches the effect of hypo-fractionated radiotherapy, also known as stereotactic body radiotherapy (SBRT), for men with prostate cancer, which is considered high risk.  SBRT is a routine treatment for prostate cancer pioneered at UCLA, which delivers five large doses of radiation rather than many small doses over a longer period of time.  This study is designed to compare the quality of life outcomes for patients who opt for SBRT over the longer course of treatment. 

Research Procedures: 
All treatment that takes place on this study is considered routine.  Patients will come to Radiation Oncology for a treatment planning session which requires a CT scan, then return about one week later to receive radiation to the pelvis on five separate occasions.  Patients will return to Radiation Oncology for regular follow-up visits for up to five years.  At all visits patients will be asked to complete quality of life questionnaires which ask about sexual health, urinary function and other personal issues pertinent to men being treated for prostate cancer. 

For More Detailed Information Contact:

  • Amar Kishan, MD, PhD., Principal Investigator 424-259-8777
  • Vicky Ramirez, Study Coordinator 310-267-8996
  • UCLA Department of Radiation Oncology
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest